Actively Recruiting
Phase 23 Double-Blind, Placebo-Controlled Trial Evaluating BHV-8000 Oral Treatment in Adults With Early Parkinsons Disease
Led by Biohaven Therapeutics Ltd. · Updated on 2026-10-22
550
Participants Needed
25
Research Sites
56 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating BHV-8000 in adults aged 40 to 80 diagnosed with early Parkinsons disease. The study aims to determine if BHV-8000 is effective, safe, and tolerable as a treatment. This Phase 23 trial is led by Biohaven Therapeutics Ltd. and includes a double-blind phase followed by an open-label phase to assess the treatments impact over time. Participants will be randomly assigned to receive either BHV-8000 at doses of 10 mg or 20 mg taken orally, or a matching placebo during the 48-week double-blind phase. After this, all participants enter a 48-week open-label phase where they receive BHV-8000. This design allows comparison between the study drug and placebo, followed by extended access to the active treatment. During the study, participants will be regularly assessed for Parkinsons disease progression using the Movement Disorder Society-Unified Parkinsons Disease Rating Scale MDS-UPDRS and other clinical measures. Safety will be monitored through recording adverse events and laboratory tests up to 96 weeks. The primary outcome is the time to first worsening event on the MDS-UPDRS Part II within 48 weeks. Participants are expected to remain in the study for up to 96 weeks of observation and treatment.
CONDITIONS
Brief Title
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Research Team
C
Chief Medical Officer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here